MBT-2-luc Orthotopic Mouse Model Service for Bladder Cancer

The MBT-2-luc orthotopic mouse model represents one of the most physiologically relevant preclinical platforms for bladder cancer research, recapitulating the tumor microenvironment, stromal interactions, and metastatic patterns observed in human disease. At Alfa Cytology, we engineer and deploy this syngeneic, immune-competent orthotopic system with integrated firefly luciferase reporter tracking, giving investigators a robust, quantifiable framework to evaluate intravesical therapies, immune checkpoint modulation, and novel targeted agents under preclinical conditions.

Overview of MBT-2-luc Orthotopic Mouse Model for Bladder Cancer

The MBT-2 cell line was originally established from a bladder tumor induced in a C3H/He mouse by serial administration of FANFT (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide), a nitrofuran compound known to generate transitional cell carcinomas in the urinary bladder. When transduced to stably express firefly luciferase (MBT-2-luc), these cells enable non-invasive, longitudinal monitoring of tumor burden through bioluminescence imaging, providing real-time quantitative readouts of tumor growth, regression, and dissemination without the need for serial sacrifice. The orthotopic implantation approach—delivering tumor cells directly into the bladder wall or lumen—preserves the native urothelial architecture, basement membrane integrity, and surrounding stromal milieu, thereby capturing critical aspects of tumor-stroma crosstalk, angiogenesis, and immune surveillance that are largely absent in subcutaneous counterparts.

Fig 1. Representative histopathological features of the orthotopic bladder cancer models: catheter and open surgery models. (Noh, Ji-In, et al., 2023)

In the orthotopic setting, MBT-2-luc tumors exhibit aggressive local invasion into the muscularis propria, with documented potential for lymphatic and distant organ spread in syngeneic C3H/He hosts. The model supports a fully functional immune system, making it particularly suited for evaluating immunotherapeutic strategies—including intravesical Bacillus Calmette-Guérin (BCG) analogs, cytokine therapies, and immune checkpoint inhibitors—within a microenvironment that mirrors human muscle-invasive bladder cancer (MIBC). Tumor take rates exceeding 90% can be achieved with optimized mucosal preconditioning protocols, while bioluminescence signal intensity correlates strongly with histopathological tumor volume, enabling preclinical pharmacodynamic assessments with high temporal resolution.

Cell Line Information: MBT-2-luc

MBT-2-luc is a luciferase-expressing derivative of the parental MBT-2 murine bladder transitional cell carcinoma line. The parental MBT-2 line was derived from a chemically induced tumor in a female C3H/He mouse and has been extensively characterized as a model of poorly differentiated urothelial carcinoma. Stable integration of the firefly luciferase reporter gene enables quantitative, non-invasive tracking of tumor dynamics in live animals via D-luciferin substrate administration and optical imaging. The cells retain the epithelial morphology, cytokeratin expression, and tumorigenic potential of the parental line while providing a sensitive optical readout for longitudinal preclinical studies.

Our Services

Alfa Cytology delivers end-to-end MBT-2-luc orthotopic model services encompassing cell line authentication, luciferase stability validation, surgical implantation, longitudinal bioluminescence imaging, and comprehensive histopathological endpoint analysis. Our team of preclinical oncology specialists tailors each study to your compound's mechanism of action, whether you are assessing intravesical drug delivery, systemic immunomodulation, or combination regimens, ensuring that every dataset is generated under rigorously controlled conditions with full traceability and regulatory-compliant documentation.

Workflow of MBT-2-luc Orthotopic Mouse Model Construction

Construction of the MBT-2-luc orthotopic bladder cancer model at Alfa Cytology follows a standardized yet customizable workflow designed to maximize tumor take rates, ensure reproducibility, and enable precise pharmacodynamic readouts. The process integrates cell quality control, optimized surgical or transurethral techniques, and rigorous in vivo monitoring protocols, all executed under IACUC-approved guidelines. Each step is documented with batch records, imaging timestamps, and health monitoring logs to support downstream data integrity and regulatory submissions.

1. Cell Preparation and Quality Control: MBT-2-luc cells are expanded from authenticated, mycoplasma-free master cell banks under BSL-1 conditions. Prior to implantation, cells are harvested at subconfluence, viability is confirmed by trypan blue exclusion (>90%), and luciferase expression is validated by in vitro D-luciferin assay to ensure consistent photon output across the batch.
2. Animal Selection and Acclimation: Female C3H/He mice, 6–8 weeks of age, are procured from certified vendors and acclimated for a minimum of 7 days under specific-pathogen-free (SPF) conditions. Baseline body weights are recorded, and animals are randomized into treatment cohorts based on weight stratification prior to tumor cell implantation.
3. Mucosal Preconditioning: To enhance tumor cell adherence and achieve take rates approaching 100%, the bladder mucosa is preconditioned via transurethral catheterization. A brief exposure to dilute acid (e.g., 0.1 N HCl for 15 seconds) followed by neutralization disrupts the urothelial barrier without inducing excessive inflammation, creating a receptive surface for tumor cell seeding.
4. Orthotopic Tumor Cell Implantation: Under general anesthesia, a single-cell suspension of 1.0–1.2 × 10⁶ MBT-2-luc cells in 50 µl of serum-free medium or PBS is instilled into the bladder lumen via a 24-gauge catheter. The urethra is temporarily ligated for 60 minutes to allow cell dwell time and attachment to the denuded mucosal surface, after which the ligature is released to restore normal micturition.
5. Post-Operative Monitoring and Recovery: Mice receive perioperative analgesia and antibiotic prophylaxis as per IACUC guidelines. Daily health assessments monitor for signs of urinary obstruction, hematuria, or systemic distress. Animals showing severe azotemia or >20% body weight loss are humanely euthanized according to predetermined humane endpoints.
6. Longitudinal Bioluminescence Imaging: Beginning 3–5 days post-implantation, tumor growth is monitored non-invasively via IVIS or equivalent optical imaging platform following intraperitoneal D-luciferin injection (150 mg/kg). Photon flux (photons/second) is quantified from defined regions of interest over the lower abdomen, with imaging frequency tailored to study duration and therapeutic intervention schedules.
7. Therapeutic Intervention and Pharmacodynamic Assessment: Upon confirmation of established tumor burden (typically Day 7–10), animals are randomized into vehicle control and treatment arms. Test articles are administered via intravesical instillation, intraperitoneal injection, or oral gavage according to the investigational protocol, with bioluminescence signals captured at predefined intervals to assess treatment response.
8. Endpoint Analysis and Histopathology: At study termination, mice are euthanized and subjected to necropsy. Bladders are harvested, weighed, and processed for H&E staining to confirm tumor grade, muscle invasion depth, and stromal response. Ex vivo bioluminescence imaging of excised organs assesses metastatic dissemination, while immunohistochemistry (IHC) or flow cytometry can be applied to characterize immune infiltrates and target engagement.

Fig 2. MBT-2-luc Orthotopic Mouse Model construction workflow.

Case Study-MBT-2-luc Orthotopic Mouse Model Development

In a representative preclinical engagement, MBT-2-luc cells were orthotopically implanted into syngeneic C3H/He mice following standardized mucosal preconditioning. Bioluminescence imaging confirmed robust tumor engraftment within one week, with signal intensity increasing logarithmically over the subsequent 14-day monitoring period. Animals were stratified into cohorts receiving either vehicle control or an investigational intravesical agent, with treatment initiated once tumors reached a predefined photon flux threshold. Longitudinal imaging revealed differential tumor growth trajectories between groups, and terminal histopathology corroborated the imaging data, demonstrating variance in tumor volume, muscle invasion depth, and lymphovascular involvement. Flow cytometric analysis of tumor-infiltrating leukocytes further elucidated treatment-induced shifts in the immune microenvironment, providing mechanistic insights into the compound's mode of action within an intact, immunocompetent bladder cancer setting. These preclinical findings supported the advancement of the therapeutic candidate into subsequent IND-enabling studies.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your MBT-2-luc orthotopic bladder cancer studies means gaining access to a preclinical infrastructure built specifically for rigorous, translationally relevant oncology research. Our differentiated capabilities span technical execution, scientific depth, and operational flexibility—ensuring that your program moves forward with confidence and speed.

• Deep expertise in orthotopic urological tumor models, with established SOPs refined across multiple bladder cancer cell lines and syngeneic host strains.
• Integrated in vivo imaging core equipped with IVIS Spectrum and advanced optical quantification software for precise, reproducible bioluminescence tracking.
• Customizable study designs accommodating intravesical, systemic, and combination dosing regimens with flexible sampling schedules and endpoint panels.
• Rigorous cell line authentication, mycoplasma screening, and luciferase stability monitoring to eliminate batch-to-batch variability and ensure data integrity.
• Comprehensive histopathology and immunoprofiling services—including H&E, IHC, multiplex immunofluorescence, and flow cytometry—available as integrated endpoints.
• Dedicated project management with transparent milestone tracking, real-time data sharing portals, and regulatory-compliant documentation packages for IND submissions.
• Competitive turnaround times from study initiation to final report, supported by in-house breeding colonies and strategic vendor partnerships that minimize procurement delays.

Contact Us

Whether you are designing a first-in-class intravesical therapy, optimizing an immune checkpoint combination, or seeking a reliable partner for longitudinal bladder cancer pharmacology studies, we invite you to reach out to us today. The Alfa Cytology team is ready to discuss your specific research objectives, propose a tailored study design, and provide a detailed quotation aligned with your timeline and budget. Contact us now to accelerate your bladder cancer preclinical program with a CRO partner committed to scientific excellence and operational precision.

For research use only. Not intended for any clinical use.